Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia by Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti

“…Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. …”
Get full text

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia by Stephen E. Langabeer, Rehman Faryal, Michael O’Dwyer, Sorcha Ní Loingsigh

“…The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effects that impact on quality of life. …”
Get full text

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia by Vihang Patel, Anil Pattisapu, Karim Attia, John Weiss

Subjects: Get full text

Basophil counting by hematology analyzers in cases of suspected chronic myeloid leukemia by Johannes J. M. L. Hoffmann

Get full text

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: MANAGEMENT APPROACHES by Vasile Musteata

“…Objective: The study objective was to analyze the short- and long-term results of treatment discontinuation in patients with chronic myeloid leukemia (CML) and complete molecular response (CMR). …”
Get full text

Dermatofibrosarcoma Protuberans and Chronic Myeloid Leukemia: A Rare Co-incidence by Jhanzeb Iftikhar, Fareeha Sheikh, Nazish Khalid, Syed Abdul Mannan Hamdani, Usman Ahmad, Umm-E-Kalsoom Awan

Subjects: “…dermatofibrosarcoma protuberans, chronic myeloid leukemia, coexisting…”
Get full text

Unique characteristics of leukocyte volume, conductivity and scatter in chronic myeloid leukemia by Balan Louis Gaspar, Prashant Sharma, Neelam Varma, Dmitry Sukhachev, Ishwar Bihana, Shano Naseem, Pankaj Malhotra, Subhash Varma

“…We compared leukocyte volume, conductivity and scatter (VCS) characteristics of chronic myeloid leukemia (CML), bcr-abl1-positive patients with those of non-neoplastic neutrophilia. …”
Get full text

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia? by Avital F. Barak, Lilach Bonstein, Roy Lauterbach, Elizabeth Naparstek, Sigal Tavor

Subjects: “…chronic myeloid leukemia, tyrosine kinase inhibitor, thrombocytopenia, HSCT…”
Get full text

Is stem cell transplantation the treatment of choice in pediatric chronic myeloid leukemia? by Daniel KL Cheuk

Get full text

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy by Matteo D’Addona, Luca Pezzullo, Valentina Giudice, Bianca Serio, Carlo Baldi, Pio Zeppa, Carmine Selleri

Subjects: Get full text

A case of juvenile chronic myeloid leukemia with XX/XXX mosaicism by M A Yeşilipek, G Lüleci, N Oygür, S Berker, O Yegin

Get full text

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis by C.R.T. Godoy, D. Levy, V. Giampaoli, D.A.F. Chamone, S.P. Bydlowski, J. Pereira

Subjects: Get full text

Megakaryocytic blast crisis in chronic myeloid leukemia: A primary presentation by Komal Mahendra Ashar, Viren Vaghasiya, Smita Chetan Patel

Get full text

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia by Stéphane Flamant, William Ritchie, Joëlle Guilhot, Jeff Holst, Marie-Laure Bonnet, Jean-Claude Chomel, François Guilhot, Ali G. Turhan, John E.J. Rasko

“…Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. …”
Get full text

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy by Rick Proschmann, Christoph Baldow, Tino Rothe, Meinolf Suttorp, Christian Thiede, Josephine T. Tauer, Martin C. Müller, Andreas Hochhaus, Ingo Roeder, Ingmar Glauche

Get full text

Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. by Michele Tanturli, Serena Giuntoli, Valentina Barbetti, Elisabetta Rovida, Persio Dello Sbarba

“…We previously demonstrated that severe hypoxia inhibits growth of Chronic Myeloid Leukemia (CML) cells and selects stem cells where BCR/Abl(protein) is suppressed, although mRNA is not, so that hypoxia-selected stem cells, while remaining leukemic, are independent of BCR/Abl signaling and thereby refractory to Imatinib-mesylate. …”
Get full text

Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia by Yvonne Lisa Behrens, Laura Gaschler, Ronny Nienhold, Thea Reinkens, Elke Schirmer, Sabine Knöß, Renate Strasser, Stephanie Sembill, Zofia Wotschofsky, Meinolf Suttorp, Manuela Krumbholz, Brigitte Schlegelberger, Markus Metzler, Gudrun Göhring, Axel Karow

Get full text

Are we ready to use precision medicine in chronic myeloid leukemia practice? by Dennis Dong Hwan Kim

Get full text

Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia by Asim F. Belgaumi, Ali Al-Shehri, Mouhab Ayas, Mohammed Al-Mahr, Amel Al-Seraihy, Ali Al-Ahmari, Hassan El-Solh

“…As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. …”
Get full text

Some Hematological Indices as Predictors of Survival in Chronic Myeloid Leukemia Patients by Yusur Falah Faraj, Khalid Mahdi Salih, Abderrahim Khelif

Subjects: Get full text